165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
Titel:
165MO Trastuzumab-deruxtecan (T-DXd) in HER2-positive breast cancer patients (pts) with active brain metastases: Primary outcome analysis from the TUXEDO-1 trial
Auteur:
Bartsch, R. Berghoff, A.S. Furtner, J. Marhold, M. Bergen, E.S. Roider-Schur, S. Starzer, A.M. Forstner, H. Rottenmanner, B. Dieckmann, K. Bago-Horvath, Z.A. Widhalm, G. Ilhan-Mutlu, A. Minichsdorfer, C. Fuereder, T. Singer, C.F. Weltermann, A. Puhr, R. Preusser, M.